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Abstract
Background: Children and adolescents with inflammatory bowel disease (IBD) are at increased risk of vaccine
preventable diseases (VPD). This includes invasive pneumococcal disease and influenza. The primary aim of this
study was to describe compliance with current Australian guidelines for vaccination of children and adolescents
diagnosed with IBD. A secondary aim was to review the serological screening for VPD.
Methods: A random sample of patients (0-18 years at diagnosis), were selected from the Victoria Australia state
based Pediatric Inflammatory Bowel Disease Register. A multi-faceted retrospective review of immunization status
was undertaken, with hospital records audited, a telephone interview survey conducted with consenting parents
and the vaccination history was checked against the primary care physician and Australian Childhood
Immunization Register (ACIR) records. The routine primary childhood vaccinations and administration of the
recommended additional influenza and pneumococcal vaccines was clarified.
Results: This 2007 audit reviewed the immunization status of 101individuals on the Victorian Pediatric IBD
database. Median age at diagnosis was 12.1 years, 50% were on active immunosuppressive therapy. 90% (38/42)
[95% confidence intervals (CI) 77%; 97%] with complete immunization information were up-to-date with routine
primary immunizations. Only 5% (5/101) [95% CI 2%; 11%] received a recommended pneumococcal vaccine
booster and 10% (10/101) [95% CI 5%; 17%] had evidence of having ever received a seasonal influenza vaccine.
Those living in rural Victoria (p = 0.005) and younger at the age of diagnosis (p = 0.002) were more likely to have
ever received an influenza vaccine Serological testing, reviewing historical protection from VPD, identified 18% (17/
94) with evidence of at least one serology sample.
Conclusion: This study highlights poor compliance in IBD patients for additional recommended vaccines. A multi-
faceted approach is required to maximize protection from VPD in this vulnerable special risk population.
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Background
The prevention of vaccine preventable diseases (VPD) in
all individuals with inflammatory bowel disease (IBD) is
increasingly recognised as important[1-3]. IBD rates
have increased globally over the past 30 years, including
in the Australian state of Victoria, where the incidence
of Crohn’s disease rose from 0.128 to 2.0 per 100 000
per year over a 31-year period (1971-2001)[4]. Immuno-
suppressive therapies such as corticosteroids and
azathioprine have long been used in IBD management.
Infliximab is one of the biologic anti-TNF-alpha anti-
body therapies, and an effective treatment for luminal
and fistulising Crohn’s disease, as well as those with a
high inflammatory disease burden[5].
The risk of opportunistic infections in IBD is
increased, particularly when on immunosuppressive
therapies, including biologics such as infliximab[6,7].
This risk is increased when combining two or more
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reports of VPD in this vulnerable group, including
severe varicella and pneumococcal pneumonia[10,11].
Viral hepatitis is also a significant risk as shown in a
number of studies[12-14]. Cheveuax et al. found evi-
dence of seroprotection from hepatitis B through immu-
nization in 48.9% of IBD patients (N = 315 patients),
with age at diagnosis (> 31 years), duration of disease
over 7 years and a diagnosis of Crohn’s disease, all asso-
ciated with the lack of effective vaccination. It is impor-
tant to consider screening for opportunistic infections as
part of the clinical approach to IBD patients and maxi-
mise prevention of these infections where possible
through immunization[15]. This has been detailed in a
number of guidelines, including the European evidence
based consensus on the prevention, diagnosis and man-
agement of opportunistic infections in inflammatory
bowel disease[16,17].
In the state of Victoria, Australia, pediatric gastroenter-
ologists care for the majority of children and adolescents
with IBD. This is predominantly at the states two tertiary
gastroenterology centres, The Royal Children’s Hospital
(RCH) and Monash Medical Centre (MMC), Melbourne.
This management in a small number of patients is shared
care with a general paediatrician, particularly for those
patients living in rural areas. As there is centralised ser-
vice delivery, Victoria has established a state-based IBD
register for children and adolescents with IBD[4].
Vaccinations in early childhood are captured in a hand
held person medical record and also on the Australian
Childhood Immunization Register (ACIR) for those < 7
years of age. At the time of the study ACIR data was
not accessible once a child was greater than 7 years.
The Australian routine funded vaccines on the National
Immunization Program are detailed in Table 1. Annual
influenza immunization is also funded for special risk
groups such as children and adolescents with IBD ≥ 6
months of age and vaccination offered from late Febru-
ary through to October. Many immunization guidelines,
including those in Australia,a r ea l s on o wr e c o m m e n d -
ing additional pneumococcal vaccine for special risk
patients, including those with IBD on immunosuppres-
sive medication[18]. The treating gastroenterologist is
often the main source of immunization advice in child-
hood and adolescent IBD, particularly if immunosup-
pressive therapy is commenced. At RCH there is an
Immunization Drop-in Centre open business hours,
staffed by nurse immunization specialists, where queries
can be directed and vaccines administered on the day of
clinic appointments. In Victoria, immunization nurse
specialist or primary care physicians administer the
majority of vaccines.
Table 1 Australian National Immunization Program (NIP)
Schedule
Age Australian Routine Schedule Vaccines by Antigen
Birth Hepatitis B
2 months Diphtheria
Tetanus
Pertussis (acellular)
Polio
Haemophilus Influenzae type b (Hib)
Hepatitis B
7-valent pneumococcal conjugate vaccine* (7vPCV)
Rotavirus
†
4 months Diphtheria
Tetanus
Pertussis
Polio
Hib
Hepatitis B
7vPCV
Rotavirus
6 months Diphtheria
Tetanus
Pertussis
Polio
Hib
Hepatitis B
7vPCV
Rotavirus
12 months Measles
Mumps
Rubella
Hib
Meningococcal C
18 months Varicella**
4 years Diphtheria
Tetanus
Pertussis
Polio
Measles
Mumps
Rubella
12-13 Years Quadrivalent Human Papillomavirus (HPV
††) vaccine
Varicella and Hepatitis B vaccine catch-up if required
15-16 years Diphtheria
Tetanus
Pertussis (acellular) [dTap ‘booster’]
*pneumococcal conjugate vaccine (PCV7) commenced January 2005 (catch-up
for children born after January 2003)
† Rotavirus vaccine program commenced June 2007
** Varicella vaccine on routine NIP schedule November 2005
†† HPV vaccine on NIP schedule April 2007- females only, catch-up 12-26 year
olds 2007-09
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compliance with current Australian guidelines for vacci-
nation of children and adolescents diagnosed with IBD
current at the time of the study[19]. A secondary aim
was to review the serological screening for VPD in
patients with IBD.
Methods
A multi-faceted retrospective review of immunization
status was undertaken, with the inclusion criteria being
age 0-18 years at diagnosis and on the IBD register.
There were a total of nine gastroenterologists working
across the two tertiary units [RCH and MMC] at the
time of the study. Hospital records of all participants
were audited, with any vaccinations administered
recorded in the outpatient notes and/or a medication
chart if administered at the RCH Immunization Drop-in-
centre. A telephone interview survey was conducted with
consenting parents using the parent-held child immuni-
zation record. The vaccination history was checked
against the primary care physician and ACIR records.
The routine primary childhood vaccinations and admin-
istration of the recommended additional influenza and
pneumococcal vaccines was clarified. Therapies were
categorized into four groups: ASA derivatives (sulphasa-
lazine, osalazine, mesalazine and balsalazide); oral corti-
costeroids (prednisolone); immunosuppressive agents
(azathioprine, methotrexate) and biologics (infliximab).
The RCH patient’s hospital laboratory results were
reviewed to identify if any baseline serological testing was
performed to review the requirement for additional pro-
tection against VPD such as varicella and hepatitis B.
Multiple sources were reviewed for any vaccine safety
concerns or reports of adverse events following immuni-
zation, including: hospital records, general practitioner
records and parent reports through interviews.
A random sample of 101 participants was taken from
the IBD register. The random sample was generated using
the statistical software STATA Version 10.0 (StataCorp,
TX), which was also used for data analysis. This overall
sample size calculation was based on the outcome of rou-
tine immunization up-to-date status by hospital medical
record audit and allowed a determination of proportions
within +/- 10% with 95% confidence. Proportions of up-
to-date status and additional vaccines administered were
compared using a Pearson chi-square test with point esti-
mate odds ratios (OR) and 95% confidence intervals deter-
mined and a p value < 0.05 considered statistically
significant. The study was approved by the Royal Chil-
dren’s Hospital Human Research Ethics Committee.
Results
The study was conducted between July-November 2007.
The participant demographics are detailed in Table 2.
There only difference at baseline between those selected
for the study, compared with the rest of the IBD data-
base (N = 534), was proportionally more cases of inde-
terminate colitis in the database group [11% versus 3%;
P = 0.01]. Participants had a median age at diagnosis of
12.1 years [range 1.9 to 17.8 years], 50% were female,
and 75% had Crohn’s disease. At the time of the immu-
nization audit 43 participants were on 5-ASA deriva-
tives: sulphasalazine (17), mesalazine (21), besalazine (4)
and osalazine (1). Reviewing ongoing immunosuppres-
sive therapies, there were 39 participants, some on mul-
tiple medications including: oral corticosteroids (7),
azathioprine (36) and infliximab (7).
One hundred and one hospital patient records were
reviewed as detailed in the study flow diagram. (Figure 1)
A telephone immunization survey was completed in 42%
and primary care practitioner records obtained in 66%
(33/50) of consenting participants. In those whom a
complete telephone immunization survey was obtained,
90% (38/42) [95% confidence intervals (CI) 77%; 97%]
w e r eu p - t od a t ew i t hr o u t i n ep r i m a r yc h i l d h o o d
immunizations.
For additional recommended vaccines, only 5% (5/
101) [95% CI 2%; 11%] had received a recommended
pneumococcal ‘booster’ and all were on active therapy
including azathioprine (4) and infliximab (1). 10% (10/
101) [95% CI 5%; 17%] had evidence of having ever
received an influenza vaccination, 7% (7/101) [95% CI
3%; 14%] in the year of the survey. Those living in
rural Victoria (Odds ratio 6.51 95% CI 1.33; 41.25, p =
Table 2 Baseline Characteristics
Characteristic Audit
(%)
IBD
Database
(%)
P
value
Sex (Female) 50 41 0.12
Diagnosis
Crohn’s disease 74 70 0.4
Ulcerative colitis 23 19 0.4
Indeterminate colitis 3 11 0.01
Length time since diagnosis (range:
years)
≤ 5years 64 55 0.12
≥6 years 36 45 0.12
Medication exposure (ever)*
Oral steroids (> 3 months duration) 77
Antiinflammatory (sulphasalazine/
osalazine/mesalazine)
88
Immunosuppressive (azothioprine or
methotrexate)
59
Biologic therapy (Anti TNF
Infliximab)
20
* some patients had multiple medications so percentages may exceed 100%
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square for trend c
2 = 16.8; p = 0.002) were more likely
to have received an influenza vaccine. The reasons for
not having received an influenza vaccine (n = 33)
included: not being aware of it (24%); concerned about
side effects (24%) not necessary (15%); doctor did not
offer it (6%), allergy (6%) and unspecified or other rea-
son (25%).
Serological testing, reviewing historical protection
from VPD, identified 18% (17/94) with evidence of at
least one serology sample. Having serology testing was
not associated with age (c
2 f o rt r e n d=1 . 7 ;p=0 . 4 2 ) .
For the patients who had varicella serology, 18% (2/11)
were negative. Pre-diagnosis varicella vaccine had been
received by 8 participants, with an additional 30 con-
firming pre-diagnosis clinical infection. There were four
Figure 1 Flow diagram of study participants.
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hepatitis B serology documented, all were negative for
hepatitis B surface antigen (HepBsAg) and seropositive
for protective anti-HepB surface antibody. On Hepatitis
B vaccination history, immunization was confirmed in
93% (39/42), including 86% (6/7) of those currently on
infliximab. The quadrivalent human papillomavirus
(4vHPV) vaccine had been administered to 14 young
women. There were no documented safety concerns or
flares of inflammatory bowel disease notified following
immunization.
Discussion
This study highlights good compliance with routine
childhood immunizations, with the 90% up-to date status
equivalent to the coverage rates of 93.6% at seen in Vic-
toria, Australia overall[20]. The uptake of recommended
additional vaccines such as annual influenza vaccination
and pneumococcal vaccine boosters was low.
There are very few published studies on compliance
guidelines on immunizations in IBD patients[2,21]. In a
United States immunization status survey of 169 adoles-
cents and adults diagnosed with IBD, 86% were using
immunosuppressive therapies[22]. On immunization sta-
tus recall only 28% had received influenza and 13%
pneumococcal vaccination. This compares with this
study of influenza vaccination confirmed in 10% and
additional pneumococcal vaccination 5%. When review-
ing other special risk groups’ compliance with recom-
mended additional vaccines, a Victorian study of
childhood cancer survivors found 47% had ‘ever’ had an
influenza vaccine[23]. This compared to 27% of children
< 7 years diagnosed with cystic fibrosis and managed at
RCH who had received an annual influenza vaccine and
37% the additional recommended pneumococcal vaccine
[ 2 4 ] .I na d d i t i o ni nas t u d yo fp r e t e r mi n f a n t sa tt w o
Victorian tertiary neonatal units, only 20% of infants
with chronic lung disease had received an influenza vac-
cine[25].
The increased risk of morbidity and mortality from
influenza infection in those with a chronic illness such
as IBD is well described and confirmed in the 2009-10
HINI influenza epidemic[26,27]. The response to influ-
enza vaccine in patients receiving immunomodulatory
therapy is variable, but usually satisfactory, as seen in an
influenza vaccine sero-response study in 146 IBD
patients, including those who were immunosuppressed
[28]. The safety of influenza vaccine in IBD patients has
been reviewed in a cohort of adult IBD patients follow-
ing H1N1 influenza vaccination [29]. Four weeks after
immunization, absence of a disease flare was observed
in 96.7% patients with Crohn’sd i s e a s ea n d9 5 . 6 %w i t h
ulcerative colitis. The importance of physician recom-
mendation for uptake of influenza vaccine, has been
highlighted in a parental survey of children with a
chronic illness[30].
Invasive pneumococcal disease (IPD) is also increased
in those with an underlying chronic illness and on
immunosuppressive therapies[31]. It is hence important
to protect IBD patients from these VPD. Australia intro-
duced a 7-valent conjugate pneumococcal vaccine
(PCV7) on 1 Jan 2005, and the special risk guidelines
current in 2007 recommended additional 7vPCV if
under 10 years and 23 valent polysaccharide vaccine
23vPPV if > 10 years of age[18]. The response in adults
to 23vPPV is variable and IBD patients on biologic
therapies such as infliximab achieve lower protective
titres[32]. Newer pneumococcal conjugate vaccines with
increasing numbers of serotypes are becoming available
internationally [33] and the 13 valent conjugate vaccine
(PCV13) introduced into a number of countries includ-
ing the United States and soon in Australia[34,35].
Importantly the PCV13 vaccine is also being studied in
adults > 50 years, and early results from phase III
immunogenicity studies found an equivalent or better
response than the 23vPPV[36]. Studies are also in pro-
gress to determine the efficacy of this vaccine in pre-
venting community acquired pneumonia in adults > 65
years[37]. Studies of these newer PCV are required in
special risk populations to assess both their safety and
immunogenicity and help determine the best schedule
to optimise IPD protection.
The risk of reactivation of diseases such as hepatitis B
by these anti-TNFa antibody therapies, has led to
recommendations of additional screening before com-
mencing therapy[38,39]. In this study 20% of partici-
pants had been treated with infliximab and other
biologic therapies may be used in the future. Reassur-
ingly, 93% (39/42) of those with comprehensive immuni-
zation records had documented evidence of hepatitis B
vaccination. However, serological testing confirming a
negative Hepatitis B infection status was conducted in
only four patients. It is possible this is an underestimate
as serology samples may have been sent to external
laboratories. Another limitation of this serological eva-
luation was that it was conducted at only one of the two
sites (RCH), but included 94% of subjects.
Live vaccines need to be considered with caution in
patients who are immunosuppressed, due to the risk of
vaccine associated morbidity such as seen with measles
vaccine[40]. Varicella vaccine was introduced into Aus-
tralian on 1 November 2005 for all children aged 18
months with a catch-up program at age 12-13 years. In
this study 9% (4/42) were found to not have a history of
clinical infection or immunization against varicella pla-
cing them at risk, similar to the 10% found in the Uni-
ted States IBD survey[22]. The morbidity of varicella in
immunosuppressed patients has led to studies
Crawford et al. BMC Gastroenterology 2011, 11:87
http://www.biomedcentral.com/1471-230X/11/87
Page 5 of 8challenging the general recommendation that this live
attenuated vaccines not be administered[41]. A case ser-
ies of six young people with IBD safely receiving vari-
cella vaccination whilst on infliximab therapy[42].
Despite small numbers of patients, it highlights the need
to discuss the risk versus benefits of live attenuated vac-
cines on a case-by-case basis. Another approach is to
review the immunization status at diagnosis and give all
recommended vaccines (e.g. varicella, hepatitis B) before
commencing immunosuppressive therapy. This, how-
ever, is becoming a smaller window of opportunity with
the earlier use of immunomodulatory therapy in IBD.
A limitation of the study is the retrospective nature of
the review in a state based IBD population. It was a
representative sample of the database, but some IBD
patients may have been excluded if seeing a private and/
or adult gastroenterologist and not placed on the regis-
t e r .O n em a j o rd i f f i c u l t yi nc o n d u c t i n gt h es t u d yw a s
uptake of ‘opt in’ consent, reflected by only 53% of ado-
lescent and young adult patients being contactable.
These are common issues in retrospective health related
research and a number of surveys have explored the
importance of exploring meaningful non-consent and
considering ‘opt out’ consent[43,44]. The study was
powered for 100 audit participants, but the results were
affected by the low recruitment for the telephone immu-
nization status review. The reported proportions of par-
ticipants receiving the additional pneumococcal and
influenza vaccines may not reflect the actual immuniza-
tion status due to this incomplete record obtainment.
The study was also underpowered to detect differences
in the characteristics of those who received influenza
vaccine. Another limitation is that the ACIR only routi-
nely captures and maintains immunization records in
children < 7 years of age, so added little information in
this predominantly adolescent population. Whilst ACIR
can include additional vaccines (e.g. influenza and pneu-
mococcal), this information is not always captured.
Suboptimal compliance with annual influenza vaccina-
tion and other additional vaccines recommended could
be due to lack of awareness or acceptance of immuniza-
tion guidelines for IBD patients. Engagement with sub-
specialists like pediatric gastroenterologists managing
these complex patients is important. As the primary
source of healthcare related advice for IBD patients, sur-
veying their opinions regarding immunization would be
helpful and lack of this information is a study limitation.
An Australian survey of adult gastroenterologists found
hepatitis B, influenza and pneumococcal vaccines were
recommended infrequently and the window before sig-
nificant immunosuppressive therapies commenced not
always being utilised[45].
Strategies to optimise protection from VPD include
education of both patients and their parents/carers, as
highlighted by the reasons given for influenza vaccina-
tion not being received. Education itself needs to be
supported by system changes and this may include
immunization reminders, which in the form of cards,
telephone and electronic, have all been shown to be
effective[46,47]. Protecting IBD patients through
“cocooning”, by ensuring parents and siblings are pro-
tected against VPD (e.g. influenza, pertussis and vari-
cella), is also recommended.
Conclusion
This study highlights a high level of vaccination cover-
age with routine scheduled vaccinations, but poor com-
pliance with current guidelines for influenza and
pneumococcal vaccination in adolescents and children
with IBD. Improving serological assessment prior to
commencing immunosuppressive therapies can help
minimise the risk of reactivation of VPD such as hepati-
tis B. An approach using both direct and indirect pro-
tective immunization strategies is required to maximise
protection from vaccine preventable diseases in this vul-
nerable population.
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